Short Communication
BibTex RIS Cite

Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2

Year 2020, Volume: 2 Issue: 1, 27 - 29, 23.04.2020

Mehmet Çıtırık

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated first case was reported in December 2019 and spread rapidly all over the world. During this period, it is emphasized that the special requirements for any ophthalmological examination should be fulfilled. An important issue for retina clinics is the intravitreal injection application. Procrastination is possible in all intravitreal injections (anti-VEGF, steroid), and a 2-3-month delay may not be a major problem for some diagnoses. However, in some patients, the result of delayed injection may be more severe. Additionally, for procedures requiring physical proximity, such as intravitreal injections and emergency surgeries, it is important to take additional precautions for COVID-19. Another issue is the use of hydroxychloroquine and chloroquine during the COVID-19 outbreak. The toxic cumulative drug dose of drugs is much more than the recommended dose for COVID-19.

Keywords

Retina Pandemi Coronavirus SARS-CoV-2 COVID-19

Supporting Institution

None

Project Number

None

Thanks

None

References

  • 1. Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, Last viewed 21 April, 2020.
  • 2. Coronavirus Disease 2019 (COVID-19), Prevent Getting Sick, How to Protect Yourself & Others. https://www.cdc.gov/coronavirus/ 2019-ncov/prevent-getting-sick/prevention.html, Last viewed 21 April, 2020.
  • 3. Minocha A, Sim SY, Than J, Vakros G. Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals. Eye (Lond). 2020 Apr 7.
  • 4. American Academy of Ophthalmology web site. Important coronavirus updates for ophthalmologists . https://www. aao.org/headline/alert-important-coronavirus-context (Last viewed 21 April, 2020.)
  • 5. Turkish Republic Ministry of Health. Scientific Commission Study. COVID-19 Guide. https://covid19bilgi.saglik.gov.tr/ depo/rehberler/COVID-19_Rehberi.pdf (Last viewed 21 April, 2020.)
  • 6.Sulman S. Hydroxychloroquine Maculopathy: An Update on Screening and Diagnosis. Retinal Physician. 2015; 12 (November 2015): 70-72.
  • 7. Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO). https://clinicaltrials.gov/ ct2/show/NCT04120883. Last viewed 21 April, 2020.
  • 8. Chin MS, Hooper LC, Hooks JJ, Detrick B. Identification of α-fodrin as an autoantigen in experimental coronavirus retinopathy (ECOR). J Neuroimmunol. 2014; 272(1-2): 42-50.

Year 2020, Volume: 2 Issue: 1, 27 - 29, 23.04.2020

Mehmet Çıtırık

Abstract

Project Number

None

References

  • 1. Coronavirus disease (COVID-19) Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, Last viewed 21 April, 2020.
  • 2. Coronavirus Disease 2019 (COVID-19), Prevent Getting Sick, How to Protect Yourself & Others. https://www.cdc.gov/coronavirus/ 2019-ncov/prevent-getting-sick/prevention.html, Last viewed 21 April, 2020.
  • 3. Minocha A, Sim SY, Than J, Vakros G. Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals. Eye (Lond). 2020 Apr 7.
  • 4. American Academy of Ophthalmology web site. Important coronavirus updates for ophthalmologists . https://www. aao.org/headline/alert-important-coronavirus-context (Last viewed 21 April, 2020.)
  • 5. Turkish Republic Ministry of Health. Scientific Commission Study. COVID-19 Guide. https://covid19bilgi.saglik.gov.tr/ depo/rehberler/COVID-19_Rehberi.pdf (Last viewed 21 April, 2020.)
  • 6.Sulman S. Hydroxychloroquine Maculopathy: An Update on Screening and Diagnosis. Retinal Physician. 2015; 12 (November 2015): 70-72.
  • 7. Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO). https://clinicaltrials.gov/ ct2/show/NCT04120883. Last viewed 21 April, 2020.
  • 8. Chin MS, Hooper LC, Hooks JJ, Detrick B. Identification of α-fodrin as an autoantigen in experimental coronavirus retinopathy (ECOR). J Neuroimmunol. 2014; 272(1-2): 42-50.
There are 8 citations in total.

Details

Primary Language English
Subjects Ophthalmology
Journal Section Short Communication
Authors

Mehmet Çıtırık

Project Number None
Publication Date April 23, 2020
Acceptance Date April 27, 2020
Published in Issue Year 2020 Volume: 2 Issue: 1

Cite

APA Çıtırık, M. (2020). Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. Clinical and Experimental Ocular Trauma and Infection, 2(1), 27-29.
AMA Çıtırık M. Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. CEOTI. April 2020;2(1):27-29.
Chicago Çıtırık, Mehmet. “Retinal Disease and Retina Clinics in Time of Global Pandemic of SARS-CoV-2”. Clinical and Experimental Ocular Trauma and Infection 2, no. 1 (April 2020): 27-29.
EndNote Çıtırık M (April 1, 2020) Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. Clinical and Experimental Ocular Trauma and Infection 2 1 27–29.
IEEE M. Çıtırık, “Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2”, CEOTI, vol. 2, no. 1, pp. 27–29, 2020.
ISNAD Çıtırık, Mehmet. “Retinal Disease and Retina Clinics in Time of Global Pandemic of SARS-CoV-2”. Clinical and Experimental Ocular Trauma and Infection 2/1 (April 2020), 27-29.
JAMA Çıtırık M. Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. CEOTI. 2020;2:27–29.
MLA Çıtırık, Mehmet. “Retinal Disease and Retina Clinics in Time of Global Pandemic of SARS-CoV-2”. Clinical and Experimental Ocular Trauma and Infection, vol. 2, no. 1, 2020, pp. 27-29.
Vancouver Çıtırık M. Retinal Disease and Retina Clinics in time of global pandemic of SARS-CoV-2. CEOTI. 2020;2(1):27-9.
 Download Cover Image

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(CC BY-NC-SA 4.0)